Patent US3776762A successfully refreshed from Google Patents.
Patent US4215200A successfully refreshed from Google Patents.
US4215200A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Chemically and enzymatically modified collagen hemostatic agent
Assignee: Cornell Research Foundation Inc
•
Filing: 1978-10-02
•
Granted: 1980-07-29
•
Expires: 1998-10-02
Abstract
Abstract Polymers of quaternary-structured collagen of minimum length, diameter and periodicity, and containing a relatively high positive electrostatic charge are claimed as hemostatic agents. Specific examples are guanidnated polymers of the type described, esterified polymers, and esterified-guanidinated polymers.
Inventors
- 👤 Teruo Miyata
- 👤 Kurt H. Stenzel
- 👤 Albert L. Rubin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:47
CPC Classifications
A; A61; A61L; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L15/325; C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; A61K; A61K38/00; A61L2400/00; A61L2400/04; Y; Y10; Y10S; Y10S128/00; Y10S128/08
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
75 words
An improved collagen hemostatic agent comprising enzyme-solubilized telopeptide-poor, crosslinked, polymeric collagen of regularly staggered quaternary structure having a minimum molecular length of 7000 A°, a minimum molecular diameter of 20 A°, a minimum periodicity of 670-700 A° and whose residual lysyl and carboxyl groups have been subjected respectively to at least one reaction selected from the group consisting of guanidination, esterification and guanidination-esterification to greatly enhance the net positive electrostatic charge of the collagen polymer.
Claim 2
Dependent Claim
75 words
An improved collagen hemostatic agent comprising enzyme-solubilized telopeptide-poor, crosslinked, polymeric collagen of regularly staggered quaternary structure having a minimum molecular length of 7000 A°, a minimum molecular diameter of 20 A°, a minimum periodicity of 670-700 A° and whose residual lysyl and carboxyl groups have been subjected respectively to at least one reaction selected from the group consisting of guanidination, esterification and guanidination-esterification to greatly enhance the net positive electrostatic charge of the collagen polymer.
Claim 3
Dependent Claim
15 words
A hemostatic agent of claim 1 which the polymeric collagen lysyl residues have been guanidinated.
Claim 4
Dependent Claim
16 words
A hemostatic agent of claim 1 in which the polymeric collagen carboxyl residues have been esterified.
Claim 5
Dependent Claim
21 words
A hemostatic agent of claim 1 in which the polymeric collagen lysyl and carboxyl residues have been guanidinated and esterified respectively.
Claim 6
Dependent Claim
15 words
A hemostatic agent of claim 1 in which the polymeric collagen is in gel form.
Claim 7
Dependent Claim
15 words
A hemostatic agent of claim 1 in which the polymeric collagen is in powdered form.
Claim 8
Dependent Claim
97 words
A process for the preparation of an improved collagen hemostatic agent which comprises extracting collagen from a source of collagen by treatment with a proteolytic enzyme, polymerizing the extract to polymeric collagen of regularly staggered quaternary structure having a minimum molecular length of 7,000 A°, a minimum molecular diameter of 20 A° and a minimum periodicity of 670-700 A°, crosslinking the extracted collagen polymer, and subjecting the crosslinked polymer to at least one reaction selected from the group consisting of esterification, guanidination and guanidination-esterification, whereby the net positive electrostatic charge of the collagen polymer is greatly enhanced.
Claim 9
Dependent Claim
97 words
A process for the preparation of an improved collagen hemostatic agent which comprises extracting collagen from a source of collagen by treatment with a proteolytic enzyme, polymerizing the extract to polymeric collagen of regularly staggered quaternary structure having a minimum molecular length of 7,000 A°, a minimum molecular diameter of 20 A° and a minimum periodicity of 670-700 A°, crosslinking the extracted collagen polymer, and subjecting the crosslinked polymer to at least one reaction selected from the group consisting of esterification, guanidination and guanidination-esterification, whereby the net positive electrostatic charge of the collagen polymer is greatly enhanced.
Claim 10
Dependent Claim
18 words
The process according to claim 7 in which the crosslinked, chemically modified polymer is converted to gel form.
Claim 11
Dependent Claim
18 words
The process according to claim 7 in which the crosslinked, chemically modified polymer is converted to powdered form.
References Cited (Backward Citations)
US2973302A
Cited
US3071477A
Cited
US3034852A
Cited
US3157524A
Cited
US3114593A
Cited
US3314861A
Cited
US3393080A
Cited
US3649347A
Cited
US3637642A
Cited
US3632361A
Cited
US3898129A
Cited
US4140537A
Cited
US4066083A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-07-29 | 1984-01-28 | 1984-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-07-29 | 1988-01-28 | 1988-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-07-29 | 1992-01-28 | 1992-07-29 | $7700.00 | Window Closed / Lapsed |